Overview

  • Product nameAnti-Apolipoprotein E antibodySee all Apolipoprotein E primary antibodies ...
  • Description
    Goat polyclonal to Apolipoprotein E
  • SpecificityTypically less than 1% cross reactivity against other types of apoLipoprotein was detected by ELISA. This antibody reacts with human apoLipoprotein E and has negligible cross-reactivity with Type A-I, A-II, B, C-I, C-II, C-III and J apoLipoproteins.
  • Tested applicationsIndirect ELISA, WB, ICC/IFmore details
  • Species reactivity
    Reacts with: Rat, Human
  • Immunogen

    Full length native protein (purified)(Human) (isolated from human plasma by density gradient centrifugation followed by HPLC purification).

  • Positive control
    • purified apolipoprotein E This antibody gave a positive result when used in the following methanol fixed cell lines: MCF-7.
  • General notesThis antibody has been used to determine that atherosclerotic lesions in the human aorta contain considerable amounts of lipoproteins. These lipoproteins were observed to be complexed with components of the extracellular matrix (especially LDL and proteoglycans). The role of these matrix-lipoprotein complexes is not entirely clear, however, animal models of atherosclerosis have shown that increased cellular proliferation and increased production of extracellular matrix components occur following injury to the intimal layer of the aorta.

Properties

Applications

Our Abpromise guarantee covers the use of ab7620 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Indirect ELISA 1/4000 - 1/8000.
WB 1/5000 - 1/10000. Predicted molecular weight: 36 kDa.
ICC/IF Use a concentration of 10 µg/ml.

Target

  • FunctionMediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues.
  • Tissue specificityOccurs in all lipoprotein fractions in plasma. It constitutes 10-20% of very low density lipoproteins (VLDL) and 1-2% of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver, brain, spleen, lung, adrenal, ovary, kidney and muscle.
  • Involvement in diseaseDefects in APOE are a cause of hyperlipoproteinemia type 3 (HLPP3) [MIM:107741]; also known as familial dysbetalipoproteinemia. Individuals with HLPP3 are clinically characterized by xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause. The vast majority of the patients are homozygous for APOE*2 alleles. More severe cases of HLPP3 have also been observed in individuals heterozygous for rare APOE variants. The influence of APOE on lipid levels is often suggested to have major implications for the risk of coronary artery disease (CAD). Individuals carrying the common APOE*4 variant are at higher risk of CAD.
    Genetic variations in APOE are associated with Alzheimer disease type 2 (AD2) [MIM:104310]. It is a late-onset neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death. Note=The APOE*4 allele is genetically associated with the common late onset familial and sporadic forms of Alzheimer disease. Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE*4 alleles in 42 families with late onset AD. Thus APOE*4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE*4 was virtually sufficient to cause AD by age 80. The mechanism by which APOE*4 participates in pathogenesis is not known.
    Defects in APOE are a cause of sea-blue histiocyte disease (SBHD) [MIM:269600]; also known as sea-blue histiocytosis. This disorder is characterized by splenomegaly, mild thrombocytopenia and, in the bone marrow, numerous histiocytes containing cytoplasmic granules which stain bright blue with the usual hematologic stains. The syndrome is the consequence of an inherited metabolic defect analogous to Gaucher disease and other sphingolipidoses.
    Defects in APOE are a cause of lipoprotein glomerulopathy (LPG) [MIM:611771]. LPG is an uncommon kidney disease characterized by proteinuria, progressive kidney failure, and distinctive lipoprotein thrombi in glomerular capillaries. It mainly affects people of Japanese and Chinese origin. The disorder has rarely been described in Caucasians.
  • Sequence similaritiesBelongs to the apolipoprotein A1/A4/E family.
  • Post-translational
    modifications
    Synthesized with the sialic acid attached by O-glycosidic linkage and is subsequently desialylated in plasma. O-glycosylated with core 1 or possibly core 8 glycans. Thr-307 is a minor glycosylation site compared to Ser-308.
    Glycated in plasma VLDL of normal subjects, and of hyperglycemic diabetic patients at a higher level (2-3 fold).
    Phosphorylation sites are present in the extracelllular medium.
  • Cellular localizationSecreted.
  • Information by UniProt
  • Database links
  • Alternative names
    • AD2 antibody
    • Alzheimer disease 2 antibody
    • Apo E antibody
    • Apo-E antibody
    • ApoE antibody
    • APOE_HUMAN antibody
    • APOEA antibody
    • Apolipoprotein E antibody
    • Apolipoprotein E3 antibody
    • ApolipoproteinE antibody
    • Apoprotein antibody
    • LDLCQ5 antibody
    • LPG antibody
    • MGC1571 antibody
    see all

Anti-Apolipoprotein E antibody images

  • Anti-Apolipoprotein E antibody (ab7620) at 1/1000 dilution (in PBS/Tween (0.01%) + 3% milk for 12 hours) + Whole cell lysate of Rat glial cells at 40 µg

    Secondary
    An HRP-conjugated Rabbit anti-goat Polyclonal at 1/200 dilution
    developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 36 kDa
    Observed band size : 35-36 kDa (why is the actual band size different from the predicted?)
    Additional bands at : 55 kDa. We are unsure as to the identity of these extra bands.

    This image is courtesy of an Abreview submitted by Fabien Gosselet

    See Abreview

  • ICC/IF image of ab7620 stained MCF-7 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal donkey serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody ab7620 at 10µg/ml overnight at +4°C. The secondary antibody (green) was DyLight® 488 donkey anti- goat (ab96931) IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

References for Anti-Apolipoprotein E antibody (ab7620)

This product has been referenced in:

See all 5 Publications for this product

Product Wall

Application Western blot
Loading amount 10 µg
Gel Running Conditions Reduced Denaturing (12)
Sample Fruit fly (Drosophila melanogaster) Cell lysate - other (s2 cells)
Specification s2 cells
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 10% · Temperature: 22°C
Username

Abcam user community

Verified customer

Submitted Dec 30 2013

Thank you for contacting us and your interest in our products.

Unfortunately, none of the three antibodies you are interested in have been tested in in both the application you are interested in with rat samples and we do not have any other an...

Read More

Thank you for your reply.


I am happy to hear that this antibody worked well for you in IHC-P. Please be advised that the code that was issued to you is a credit note, since the information on our website was found to be incorrect. It ca...

Read More

Thank you for your inquiry.


I heard back from the supplying laboratory that this antibody has not, in fact, been tested in IHC-P. Data for IHC-P for their anti-ApoA2 antibody (which is produced to similar specifications) suggests the an...

Read More
Application Western blot
Sample Rat Cell lysate - whole cell (glial cells)
Loading amount 40 µg
Specification glial cells
Gel Running Conditions Reduced Denaturing (10)
Blocking step Milk as blocking agent for 20 minute(s) · Concentration: 3% · Temperature: RT°C
Username

Dr. GOSSELET Fabien

Verified customer

Submitted Nov 30 2010

I'm sorry to hear you are having problem with ab7620. This is the first complaint we receive about this popular antibody. We would recommend using this antibody at a 1:5000 to 1:10 000 dilution, and I am puzzled at why you detect an 85kDa band. Hav...

Read More

Thank you for your enquiry. The antibody was made against whole apo E. It should react with all isoforms which enrich in Human plasma. If you have any further questions please do not hesitate to get in touch.

Thank you for your enquiry. Ab7620 has been tested with cross-reactivity with human and has not yet been tested in other species. We do not routinely offer free or trial sized samples for testing purposes. Our policy at Abcam is that if an antibody...

Read More

No, the Abcam search engine will have recognised the "E" in the search term that you provided. A search for "cathepsin" identifies a number of antibodies to Cathepsin B, D, H & L, but unfortunately, we do not have an antibody to Cathepsin E.

This antibody is a polyclonal and will therefore recognise a number of epitopes

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"